Skip to main navigation menu Skip to main content Skip to site footer

Vol. 12 No. 12 (2025)
International Multidisciplinary Journal for Research & Development

Articles

RECOVERY RATE AND LONG-TERM PROGNOSIS OF GUILLAIN–BARRE SYNDROME

Published 2025-12-15

  • Abdukadirova D.T.
    • ,
  • Abdulhamidov M.A.

Abdukadirova D.T.
PhD, Associate Professor

Abdulhamidov M.A.
Andijan State Medical Institute, Department of Neurology

Abstract

Guillain–Barre syndrome (pronounced gee-YAN buh-RAY) is a disorder in which the body’s immune system attacks the nerves. It can lead to weakness, tingling, or paralysis. Weakness and tingling (paresthesia) in the hands and feet are usually the initial symptoms. These sensations can rapidly spread throughout the body, resulting in paralysis. The most severe forms of Guillain–Barré syndrome are considered medical emergencies. Most patients with this condition require hospitalization. Guillain–Barré syndrome is rare, and its exact cause is unknown. However, in approximately two-thirds of patients, signs of infection are observed within six weeks prior to the onset of Guillain–Barré symptoms. These infections may include respiratory or gastrointestinal tract infections, including COVID-19. The Zika virus can also trigger Guillain–Barré syndrome. Currently, there is no definitive cure for Guillain–Barré syndrome. Nevertheless, several treatment methods can alleviate symptoms and accelerate the recovery process. Most patients recover completely from the disease, although some severe cases may result in death.

Keywords

Guillain–Barre syndrome, immune system, nervous system, weakness, tingling (paresthesia), paralysis, weakness of the hands and feet, inpatient treatment, infection, gastrointestinal infection, COVID-19, Zika virus.

PDF

References

  1. Van Doorn P.A., Ruts L., Jacobs B.C., et al. European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of Guillain-Barré syndrome. European Journal of Neurology. 2023;30:3646–3674.
  2. Yusari I.G.A.A.A., Sudira P.G., Samatra D.P.G.P. Clinical characteristics of Guillain-Barré syndrome in COVID-19: a systematic review and meta-analysis. Egyptian Journal of Neurology, Psychiatry and Neurosurgery. 2023;59:40.
  3. Ali B.M., Hasan M.M., Rahman M.S., et al. Guillain-Barré syndrome: a review of immunotherapy, rehabilitation, and long-term outcomes. International Journal of Community Medicine and Public Health. 2023;10(12):5038–5043.
  4. Amin W., Arshad S., Khalid A., et al. Clinical outcome of Guillain-Barré syndrome in the intensive care unit of a pediatric tertiary care hospital. Biological and Clinical Sciences Research Journal. 2023;4(1):570.
  5. Kudratov F.O. Clinical and neurophysiological characteristics of patients with Guillain-Barré syndrome. Innovative Development in Research and Education. 2023;2(22):257–260.
  6. Ismoilov B.A., Karimov J.K., et al. In the early stages of Guillain-Barré syndrome, gangliosides (GM1 autoantibodies and GM1) in the blood serum. Innovative Models in Education Systems. 2023;3(34).
  7. Zhang Y., Liu X., Chen J. Guillain-Barré syndrome with compressive myelopathy: a case report. Intelligent Pharmacy. 2023;1(4):283–285.
  8. Rodrigues L.D., Silva A.C., Pereira R.M., et al. Pediatric Guillain-Barré syndrome: a case series. Research, Society and Development. 2023;12(13):e99121344236.
  9. Finsterer J., Scorza F.A. Immunological, clinical, and epidemiological features of Guillain-Barré syndrome associated with SARS-CoV-2. Journal of Medical Virology. 2023;95:e5380946.
  10. Ayraler A.
  11. COVID-19 infection and Guillain-Barré syndrome: a case report. Ordu University Medical Journal. 2023;10(3):143–147.
  12. Wang L., Chen Y., Li S., et al. Knowledge mapping and bibliometric analysis of Guillain-Barré syndrome research from 2013 to 2023. Frontiers in Neurology. 2023.
  13. Hughes R.A.C., Cornblath D.R., et al. Predictors of mechanical ventilation in axonal subtypes of Guillain-Barré syndrome. Canadian Journal of Neurological Sciences. 2023;50:221–227.
  14. Khan F., Amatya B., Galea M.P. Plasma exchange versus intravenous immunoglobulin for severe Guillain-Barré syndrome: a systematic review. eNeurologicalSci. 2023;31:100468.
  15. Martin T., Lefèvre G., Arnaud L. Guillain-Barré syndrome revealing systemic lupus erythematosus: a case report. Rheumatology. 2023;62(Suppl 3).
  16. Ahmed R., Malik A., Iqbal M., et al. Clinical, demographic and neurophysiological features of Guillain-Barré syndrome. The Professional Medical Journal. 2023;30(6):742–748.

Downloads

Download data is not yet available.